Page 19 - Read Online

Page 14 of 14 Monge Bonilla et al. Hepatoma Res 2020;6:68 I http://dx.doi.org/10.20517/2394-5079.2020.58

90. Bang Y, Golan T, Lin C, Dahan L, Fu S, et al. Ramucirumab (Ram) and durvalumab (Durva) treatment of metastatic non-small cell lung
cancer (NSCLC), gastric/gastroesophageal junction (G/GEJ) adenocarcinoma, and hepatocellular carcinoma (HCC) following progression
on systemic treatment(s). JCO 2019;37:2528.
91. Yau T, Kang Y, Kim T, El-khoueiry AB, Santoro A, et al. Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts)
with advanced hepatocellular carcinoma (aHCC): results from CheckMate 040. JCO 2019;37:4012.
92. Kudo M, Motomura K, Wada Y, Inaba Y, Sakamoto Y, et al. First-line avelumab + axitinib in patients with advanced hepatocellular
carcinoma: Results from a phase 1b trial (VEGF Liver 100). JCO 2019;37:4072.
93. Duffy AG, Ulahannan SV, Makorova-Rusher O, Rahma O, Wedemeyer H, et al. Tremelimumab in combination with ablation in patients
with advanced hepatocellular carcinoma. J Hepatol 2017;66:545-51.
94. Katz SC, Burga RA, McCormack E, Wang LJ, Mooring W, et al. Phase I hepatic immunotherapy for metastases study of intra-arterial
chimeric antigen receptor-modified T-cell therapy for CEA+ liver metastases. Clin Cancer Res 2015;21:3149-59.
95. Zhai B, Shi D, Gao H, Qi X, Jiang H, et al. A phase I study of anti-GPC3 chimeric antigen receptor modified T cells (GPC3 CAR-T) in
Chinese patients with refractory or relapsed GPC3+ hepatocellular carcinoma (r/r GPC3+ HCC). JCO 2017;35:3049.
96. Yu X, Zhao H, Liu L, Cao S, Ren B, et al. A randomized phase II study of autologous cytokine-induced killer cells in treatment of
hepatocellular carcinoma. J Clin Immunol 2014;34:194-203.
97. Lee JH, Lee JH, Lim YS, Yeon JE, Song TJ, et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for
hepatocellular carcinoma. Gastroenterology 2015;148:1383-91.e6.
98. Tan AT, Yang N, Lee Krishnamoorthy T, Oei V, Chua A, et al. Use of expression profiles of HBV-DNA integrated into genomes of
hepatocellular carcinoma cells to select T cells for immunotherapy. Gastroenterology 2019;156:1862-76.e9.
99. Wisskirchen K, Metzger K, Schreiber S, Asen T, Weigand L, et al. Isolation and functional characterization of hepatitis B virus-specific
T-cell receptors as new tools for experimental and clinical use. PLoS One 2017;12:e0182936.
100. Gehring AJ, Xue SA, Ho ZZ, Teoh D, Ruedl C, et al. Engineering virus-specific T cells that target HBV infected hepatocytes and
hepatocellular carcinoma cell lines. J Hepatol 2011;55:103-10.
101. Qasim W, Brunetto M, Gehring AJ, Xue SA, Schurich A, et al. Immunotherapy of HCC metastases with autologous T cell receptor
redirected T cells, targeting HBsAg in a liver transplant patient. J Hepatol 2015;62:486-91.
102. Sahin U, Türeci Ö. Personalized vaccines for cancer immunotherapy. Science 2018;359:1355-60.
103. Buonaguro L; HEPAVAC Consortium. Developments in cancer vaccines for hepatocellular carcinoma. Cancer Immunol Immunother
2016;65:93-9.
104. Nakagawa H, Mizukoshi E, Kobayashi E, Tamai T, Hamana H, et al. Association between high-avidity T-cell receptors, induced by alpha-
fetoprotein-derived peptides, and anti-tumor effects in patients with hepatocellular carcinoma. Gastroenterology 2017;152:1395-406.e10.
105. Sawada Y, Yoshikawa T, Nobuoka D, Shirakawa H, Kuronuma T, et al. Phase I trial of a glypican-3-derived peptide vaccine for advanced
hepatocellular carcinoma: immunologic evidence and potential for improving overall survival. Clin Cancer Res 2012;18:3686-96.
106. Sawada Y, Yoshikawa T, Shimomura M, Iwama T, Endo I, et al. Programmed death-1 blockade enhances the antitumor effects of peptide
vaccine-induced peptide-specific cytotoxic T lymphocytes. Int J Oncol 2015;46:28-36.
107. Greten TF, Forner A, Korangy F, N’Kontchou G, Barget N, et al. A phase II open label trial evaluating safety and efficacy of a telomerase
peptide vaccination in patients with advanced hepatocellular carcinoma. BMC Cancer 2010;10:209.
108. Harrington K, Freeman DJ, Kelly B, Harper J, Soria JC. Optimizing oncolytic virotherapy in cancer treatment. Nat Rev Drug Discov
2019;18:689-706.
109. Heo J, Reid T, Ruo L, Breitbach CJ, Rose S, et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-
594 in liver cancer. Nat Med 2013;19:329-36.
110. Park B, Hwang T, Liu T, Sze DY, Kim J, et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or
metastatic liver cancer: a phase I trial. Lancet Oncology 2008;9:533-42.
111. Moehler M, Heo J, Lee HC, Tak WY, Chao Y, et al. Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients
with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE). Oncoimmunology
2019;8:1615817.
112. Ma C, Han M, Heinrich B, Fu Q, Zhang Q, et al. Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells.
Science 2018;360:eaan5931.